Talphera, Inc. has 11 Schedule 13D or 13G filings on record since 2025-09-12. 4 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| CorMedix Inc. | 19.95% | 9,090,909 | SCHEDULE 13D, 2025-09-12 | 2025-09-07 |
| Rosalind Advisors, Inc. | 9.9% | 12,913,182 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Orin Hirschman | 9.8% | 4,661,502 | SCHEDULE 13G/A, 2026-01-30 | 2025-12-31 |
| Rock Springs Capital Management LP | 7.88% | 3,589,186 | SCHEDULE 13G, 2025-09-12 | 2025-09-10 |
| Lytton Laurence W | 2.5% | 1,246,444 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Purpose of Transaction (Item 4)
CorMedix Inc.
On September 7, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with the Reporting Person, pursuant to which the Reporting Person purchased from the Issuer in a private placement 9,090,909 Shares at a purchase price of $0.55 per share upon the First Closing (as defined in the Purchase Agreement). The First Closing occurred on September 10, 2025. Upon the First Closing, the Reporting Person has the right, subject to compliance with the applicable rules and regulations of The Nasdaq Capital Market, to designate one member of the Issuer's board of directors as long as the Reporting Person or its affiliates beneficially own at least 25% of the Shares the Reporting Person purchased at the First Closing. Additionally, pursuant to the Purchase Agreement, following the public announcement by the Issuer of the achievement of the primary endpoint and topline clinical data and results of the NEPHRO CRRT clinical study for the Issuer's product candidate Niyad (the "Public Announcement"), the Reporting Person shall have the right for 60 days thereafter (the "Exclusivity Period") to negotiate exclusively with the Issuer with respect to an acquisition of 100% of the capital stock and equity interests of the Issuer (the "Acquisition Transaction"). During the Exclusivity Period, the Issuer agreed that it shall not engage in discussions with any other third party about an Acquisition Transaction, a sale or exclusive license of all or substantially …The first part of Item 4 of the SCHEDULE 13D filed 2025-09-12; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-12 | Rock Springs Capital Management LP | 7.88% | SCHEDULE 13G |
| 2025-09-12 | CorMedix Inc. | 19.95% | SCHEDULE 13D |
| 2025-09-16 | Lytton Laurence W | 8% | SCHEDULE 13G |
| 2025-11-10 | Orin Hirschman | 9.7% | SCHEDULE 13G |
| 2025-11-13 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-01-30 | Orin Hirschman | 9.8% | SCHEDULE 13G/A |
| 2026-02-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Lytton Laurence W | 5.9% | SCHEDULE 13G/A |
| 2026-05-12 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Lytton Laurence W | 2.5% | SCHEDULE 13G/A |
| 2026-08-12 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Talphera, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.